CompanyGraph
Sells two FDA-approved cancer drugs, both made from the same molecule, for kidney cancer and thyroid cancer.
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- ScaleMarket cap is above the global median
- FinancialsAltman Z-Score: safe zone
- Interpretations10 currently firing — 10
What this company is and how it runs — written from structure, not news.
Exelixis sells two cancer drugs — CABOMETYX for renal cell carcinoma and COMETRIQ for medullary thyroid cancer — both made from the same molecule, cabozantinib, which blocks four separate proteins that drive tumour growth simultaneously, something no competing drug currently does in a single dose. Because each approval required its own multi-year Phase III trial and its own regulatory submission, oncologists, insurers, and specialty pharmacies have built separate prior-authorisation workflows around each indication, which makes switching to a rival drug costly for everyone in the chain. Expanding into a new cancer type does not get easier over time — every additional indication needs another Phase III trial lasting three to five years, so revenue growth moves at the pace of clinical site enrolment rather than at the pace of manufacturing. The whole structure sits on a single chemical entity, so if cabozantinib's patent expires or is successfully challenged before a successor molecule reaches approval, both approved products and all the administrative infrastructure built around them collapse at once with nothing to replace the revenue.
How does this company make money?
The company earns revenue each time CABOMETYX tablets or COMETRIQ capsules are shipped to specialty distributors and hospital systems. Revenue is recorded at the point of shipment. The final amount collected depends on negotiations with insurance payers and on discounts applied through patient assistance programs that help cover costs for eligible patients.
What makes this company hard to replace?
Before an oncologist can prescribe CABOMETYX, they must document that the patient already failed anti-angiogenic therapy and then obtain prior authorization from the patient's insurance plan — a process built specifically around this drug. Patients who are already taking cabozantinib and managing its side effects are reluctant to switch to a different kinase inhibitor that comes with a different and unfamiliar set of side effects. Specialty pharmacy networks that have already set up distribution, prior authorization workflows, and patient support services for CABOMETYX face their own costs and friction in switching to an alternative.
What limits this company?
The only way to grow into new cancers is to run a separate Phase III clinical trial for each one, and those trials take three to five years. The drug itself can be manufactured efficiently once the ingredient supply is in place, but finding and enrolling enough patients with the right cancer type at qualified trial sites is slow and cannot be sped up by spending more money. Each new indication is its own years-long project.
What does this company depend on?
The company cannot operate without FDA approval for CABOMETYX in renal cell carcinoma and FDA approval for COMETRIQ in medullary thyroid cancer — lose either and that product cannot be sold. It also depends on contract manufacturers to supply the cabozantinib active pharmaceutical ingredient, on oncology clinical trial sites capable of enrolling advanced cancer patients to expand into new indications, and on its partnership with Genentech for COTELLIC commercialization rights.
Who depends on this company?
Oncologists treating advanced renal cell carcinoma would lose a key second-line treatment option for patients who have already tried anti-angiogenic therapy. Endocrinologists managing progressive medullary thyroid cancer would lose the main targeted drug available for patients whose disease has spread. Specialty oncology pharmacies that dispense CABOMETYX and COMETRIQ — and run the prior authorization and patient assistance programs around them — would lose a significant oral cancer medication from their operations.
How does this company scale?
Once the cabozantinib drug supply is secured, making more tablets and capsules through contract manufacturing is relatively straightforward and does not hit hard limits quickly. What does not scale easily is expansion into new cancer types — every new indication requires its own Phase III trial, its own patient population, its own regulatory submission, and its own commercial launch, none of which can be shared or recycled from a prior approval.
What external forces can significantly affect this company?
Medicare Part D coverage decisions directly affect whether patients can afford CABOMETYX, since it is a high-cost oral cancer drug. The European Medicines Agency has its own trial design requirements that may not line up with what the FDA needed, forcing parallel development work. And policies governing how long a drug's patent exclusivity lasts before generics are allowed in determine exactly how much time cabozantinib has before cheaper copies can enter the market.
Where is this company structurally vulnerable?
If the patent on cabozantinib expires or a generic manufacturer successfully challenges it in court before a replacement drug reaches approval, other companies can legally copy the molecule. That would collapse sales of both CABOMETYX and COMETRIQ at the same time, because both products are the same underlying chemical — and there is no approved backup drug ready to replace that revenue.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
10 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Three observations have aligned: most-recent-quarter total cash is in the upper portion of its mapped range against most-recent-quarter total debt, EBITDA-to-total-liabilities is in the upper portion of its mapped range, and FCF-to-total-liabilities is in the upper portion of its mapped range.
How does this company use capital?
Three Asset-Base Ratios Elevated
Three asset-base observations have aligned: industry-benchmarked asset turnover is in the upper peer range, operating-income-to-total-assets is in the upper portion of its mapped range (scaled to 20%), and gross-profit-to-total-assets is in the upper portion of its mapped range (scaled to 50%).
Cash Backing With Revenue And Income Streaks
Three observations co-occur: the weighted composite of net cash relative to market cap, OCF/revenue, operating margin, and ROE is in its elevated range; revenue increased every year for three years; net income was positive every year for three years. The configuration describes a present-state combination of capital structure, cash generation, profitability, and top-line growth.
Industry-Benchmarked ROA and Margin Elevated
Three industry-benchmarked observations co-occur: median 5-year ROA and operating margin sit at the upper end of the industry peer range, gross margin is elevated, and return on equity is elevated. The configuration describes peer-relative profitability persistence, not a specific competitive mechanism.
Industry-Benchmarked Return on Capital Elevated
Three industry-benchmarked observations co-occur: return on equity is elevated, asset turnover is elevated, and return on assets is elevated. Because asset turnover and ROA both fire alongside ROE, the elevated ROE is not solely a leverage effect.
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Three margin observations have aligned: industry-benchmarked gross profit margin is in the upper peer range, operating income margin is in the upper portion of its mapped range, and industry-benchmarked net profit margin is in the upper peer range.
ROE, ROA, And Operating ROA Elevated
Three industry-benchmarked return-on-capital ratios are simultaneously in their elevated ranges: ROE, ROA, and operating ROA. Because ROA and operating ROA both fire alongside ROE, the configuration is not solely a function of equity multiplier; the underlying asset base is also producing elevated returns relative to peers.
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
Revenue Growth With Elevated Margin
Three observations align on a healthy multi-year growth profile: revenue grew every year over the trailing five-year window, operating margin in the most recent year is at an elevated level, and revenue grew every year over the trailing three-year window. Together they describe sustained top-line continuity at a high current margin level.
How is this stock valued?
Down-Close Streak With Profitability
Three observations describe the present configuration: the most recent run of consecutive down-close weeks is at or near the configured ceiling, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked equity ratio is in the upper range against peers.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.